scholarly journals A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report

2015 ◽  
pp. 2097
Author(s):  
Eriko Takatori ◽  
Tadahiro Shoji ◽  
Takayuki Nagasawa ◽  
Satoshi Takeuchi ◽  
Akira Hosoyachi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Ovarian Cancer Patient ◽  
Complete Response ◽  
Recurrent Ovarian Cancer ◽  
Weekly Paclitaxel ◽  
Prior Chemotherapy ◽  
History Of

Beyond the Beyond: First Case of 9 Cytoreductive Surgeries in a Long-Surviving Ovarian Cancer Patient: Case Report

2016 ◽  
Vol 102 (2_suppl) ◽  
pp. S78-S81 ◽  
Author(s):  
Laura Salerno ◽  
Claudia Marchetti ◽  
Elisa Bevilacqua ◽  
Angela Musella ◽  
Lucia Riganelli ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Ovarian Cancer Patient ◽  
Patient Case ◽  
First Case

scholarly journals Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report

2019 ◽  
Vol 10 (7) ◽  
pp. 247-255
Author(s):  
Mona Passler ◽  
Eliane T Taube ◽  
Jalid Sehouli ◽  
Klaus Pietzner
Keyword(s):  
Ovarian Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Ovarian Cancer Patient

scholarly journals Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples

2012 ◽  
Vol 5 (1) ◽  
pp. 2 ◽  
Author(s):  
Michael F Gallagher ◽  
Cynthia CBB Heffron ◽  
Alexandros Laios ◽  
Sharon A O'Toole ◽  
Brendan Ffrench ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patient ◽  
Ovarian Cancer Patient ◽  
Recurrent Ovarian Cancer ◽  
Cancer Stemness

Case report of a rare variant of BRCA2 germline mutation in an ovarian cancer patient

2020 ◽  
Vol 18 (4) ◽  
Author(s):  
Sudha S. Murthy ◽  
Vaishnavi Kunteepuram ◽  
Krishna Mohan Mallavarapu ◽  
T. Nageswara Rao ◽  
B. Vishal Rao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Rare Variant ◽  
Germline Mutation ◽  
Ovarian Cancer Patient

scholarly journals A pivotal role of team medicine for recurrent ovarian cancer patient affected by Clostrioides difficile enterocolitis

2019 ◽  
Vol 30 ◽  
pp. vi148
Author(s):  
Kenzo Sonoda ◽  
Rie Sugimoto ◽  
Yoriko Ando ◽  
Seiko Miyamoto ◽  
Aya Matsukura ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patient ◽  
Ovarian Cancer Patient ◽  
Recurrent Ovarian Cancer ◽  
Pivotal Role

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 5520-5520
Author(s):  
JUNG-YUN LEE ◽  
Byoung-Gie Kim ◽  
Jae-Weon Kim ◽  
Jung Bok Lee ◽  
Eunhyang Park ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Targeted Therapy ◽  
Adverse Events ◽  
Synergistic Effects ◽  
Single Agent ◽  
Objective Response ◽  
Complete Response ◽  
Recurrent Ovarian Cancer ◽  
Weekly Paclitaxel ◽  
Platinum Resistant

5520 Background: Heavily treated platinum-resistant ovarian cancer remains a therapeutic challenge. Although standard therapy includes non-platinum single agent chemotherapy (CT), prognoses are very poor in this setting. Anticancer therapies based on molecular biomarkers have improved dramatically. We report data from an umbrella study of biomarker-driven targeted therapy (olaparib, O; cediranib, C; durvalumab, D; tremelimumab, T) in platinum-resistant recurrent ovarian cancer (NCT03699449). Methods: Patients with platinum-resistant ovarian cancer with ≥ two lines of prior chemotherapy and ECOG 0/1 were eligible for this study. In the screening phase, archival tumor samples were tested for HRD and PD-L1 status. Treatment arms were allocated according to the test results. For HRD+ patients, we tested the synergistic effects of O with other agents: patients were randomly allocated to arm 1, O+C (O 200mg bid + C 30mg qd); or arm 2, O+D (O 300mg bid + D 1500mg q4w). For HRD- patients, we tested the role of biomarker-driven immunotherapy according to PD-L1 expression: arm 3, D+CT (D 1500mg q4w + PLD or topotecan or weekly paclitaxel [6 cycles]) in patients with high PD-L1 expression; arm 4, D+T75+CT (D 1500mg q4w + T 75mg q4w [4 doses] + PLD or topotecan or weekly paclitaxel [4 cycles]) in patients with low PD-L1 expression; or arm 5, D+T300+CT (D 1500mg q4w + T 300mg [1 dose] + weekly paclitaxel [60mg/m2 D1,8,15 q4w for 4 cycles]) in patients with low PD-L1 expression. Recruitment to arm 5 was initiated after completion in arm 4. The primary endpoint was objective response rates (ORR) according to RECIST 1.1. Results: Between Dec 2018 and Oct 2020, 70 patients were allocated to treatment as follows: arm 1 (n = 16), arm 2 (n = 14), arm 3 (n = 5), arm 4 (n = 18), and arm 5 (n = 17). Median age was 57 years (range 34-77) and median prior lines of treatment was 3 (range: 2-10). Among all patients, the ORR was 35.7% (25/70, 95% CI: 24.6%-48.0%); complete response was observed in two patients. The ORRs (95% CI) for each treatment arm were shown (Table). Treatment-related grade 3/4 adverse events were reported in 37.5%, 35.7%, 20%, 66.7%, and 35.3% of patients in each treatment arm, respectively. No treatment-related adverse events (TRAEs) leading to discontinuation of treatment and no grade 5 TRAEs were observed. Conclusions: This is the first biomarker-driven umbrella study conducted in patients with platinum-resistant recurrent ovarian cancer. This umbrella study provides preliminary evidence on the clinical benefit of biomarker-driven targeted therapy. All regimens were manageable, without unexpected toxicities. Clinical trial information: NCT03699449. [Table: see text]

scholarly journals History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium

2017 ◽  
Vol 28 (5) ◽  
pp. 469-486 ◽  
Author(s):  
Albina N. Minlikeeva ◽  
◽  
Jo L. Freudenheim ◽  
Rikki A. Cannioto ◽  
J. Brian Szender ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Heart Disease ◽  
Cancer Patient ◽  
Ovarian Cancer Patient ◽  
Patient Survival ◽  
History Of
Sign in / Sign up

Export Citation Format

Share Document